Extract
For decades inhaled corticosteroids have been central to the management of asthma and are proven to be effective in maintaining symptom control, reducing exacerbations and preserving quality of life through mediation of airway inflammation. However, a small minority of patients have disease which is refractory to high dose inhaled corticosteroid (ICS) therapy and require additional oral corticosteroids to achieve acceptable control of symptoms and exacerbations. Severe asthma represents less than 10% of the total asthma population [1] but is the most serious, life-affecting and costly form of the condition [2].
Abstract
Inhaler adherence may inform response to asthma biologic therapy and should continue to be assessed in patients receiving these treatments https://bit.ly/2RjMBED
Footnotes
Conflict of interest: R.W. Costello reports grants and personal fees for lectures from Aerogen and GSK, personal fees for lectures from Boehringer Ingelheim, Novartis and TEVA, outside the submitted work; and has a patent EP12182189.6 licensed.
Conflict of interest: B. Cushen has nothing to disclose.
- Received April 1, 2020.
- Accepted April 2, 2020.
- Copyright ©ERS 2020